Abstract: Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1?, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1?, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof.

Abstract: Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1(3, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1?, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof.